↓ Skip to main content

Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art

Overview of attention for article published in Vaccine, September 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

8 tweeters


16 Dimensions

Readers on

95 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art
Published in
Vaccine, September 2015
DOI 10.1016/j.vaccine.2015.07.102
Pubmed ID

Zheng Quan Toh, Paul V. Licciardi, James Fong, Suzanne M. Garland, Sepehr N. Tabrizi, Fiona M. Russell, Edward K. Mulholland


Human papillomavirus (HPV) infection is the primary cause of genital warts, some oropharyngeal cancers and anogenital cancers, including cervical, vagina, vulvar, anal and penile cancers. Primary prevention of cervical cancer requires the prevention of high-risk HPV infections, particularly HPV genotypes 16 and 18. Both Gardasil(®) and Cervarix(®) vaccines when administered by a three-dose schedule have been demonstrated to be effective against cervical, vulva, and vagina cancer precursors from vaccine genotypes in phase III clinical trials, and post-marketing studies; Gardasil(®) vaccine also offer additional protection against anal cancer precursors. However, high costs of HPV vaccines and the logistics of delivering a three-dose schedule over 6 months are challenging in countries with limited resources. Several studies have demonstrated non-inferiority in antibody response between adolescents (9-15 years old) who received two doses (6 months apart) and women (>15 years old) who received the standard three-dose schedule. These studies provided evidence for the World Health Organization and European Medical Association to revise its recommendation to give two instead of three doses of HPV vaccine to adolescents below 15 years of age, provided the 2nd dose is given 6 months apart. Although reduced dose schedules can alleviate costs and logistics associated with HPV vaccination, especially in resource-poor countries, there are still gaps in this area of research, particularly regarding long-term protection. This review discusses the findings on antibody response and clinical outcomes in studies evaluating reduced dose HPV schedules, and highlights the important considerations of its implementation. In addition, other important immunological biomarkers that may be associated with long-term protection are highlighted and discussed.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
Ecuador 1 1%
Unknown 93 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 18%
Student > Bachelor 14 15%
Researcher 12 13%
Student > Ph. D. Student 8 8%
Student > Postgraduate 7 7%
Other 21 22%
Unknown 16 17%
Readers by discipline Count As %
Medicine and Dentistry 25 26%
Biochemistry, Genetics and Molecular Biology 13 14%
Immunology and Microbiology 8 8%
Pharmacology, Toxicology and Pharmaceutical Science 6 6%
Agricultural and Biological Sciences 5 5%
Other 16 17%
Unknown 22 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 September 2015.
All research outputs
of 15,555,405 outputs
Outputs from Vaccine
of 12,632 outputs
Outputs of similar age
of 236,828 outputs
Outputs of similar age from Vaccine
of 183 outputs
Altmetric has tracked 15,555,405 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 12,632 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 236,828 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 183 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.